NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • Welcome Guide
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Case Studies
    • Patient and Public Involvement and Engagement (PPIE) Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
    • Public events
    • Patient & Public Involvement events
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Cancer > First person receives drug designed to re-sensitise patients to cancer treatment

First person receives drug designed to re-sensitise patients to cancer treatment

10 August 2021 · Listed under Cancer

The first patient has been dosed using a new drug aimed at improving treatment options for melanoma and non-small cell lung cancer (NSCLC) and re-sensitising patients with checkpoint therapy-resistant tumours

The IMP-MEL clinical trial began in Oxford with its first patient being dosed with the new drug PORT-2. The Oxford-led study is investigating the tolerability and efficacy of PORT-2, a drug that was developed to target invariant natural killer T (iNKT) cells and trigger a cancer-specific B and T cell response to tumours.

The study, which is supported by the NIHR Oxford Biomedical Research Centre (BRC), is expected to enrol 100 patients in Oxford and other centres, and will evaluate PORT-2 both as a monotherapy and in combination with approved PD-1 inhibitor drug Keytruda in the treatment of melanoma and NSCLC.

An additional aspect of the PORT-2 drug is that it has the potential to re-sensitise checkpoint-resistant tumours to treatment with PD-1 antibodies. Not all patients’ tumours respond to current immune-oncology agents, with most cancer types totally insensitive to treatment.

Re-sensitising patients is one approach to make existing cancer drugs more effective and appropriate in the treatment of many patients’ cancers.

Professor Mark Middleton, Head of the University of Oxford’s Department of Oncology and the Oxford BRC’s Co-theme Lead for Cancer, said: “Checkpoint inhibitor therapies have enormous opportunity in the treatment of solid tumours, but unfortunately, many cancers develop a resistance to these therapies, leaving many patients without adequate treatment options.

“We’re constantly seeking new therapies that are capable of addressing resistance and enabling a durable response in patients with cancer. Should PORT-2 prove successful, this novel iNKT agonist therapy could potentially re-sensitise patients to checkpoint inhibitor treatment and could activate that durable immune response. It’s a very exciting new avenue for oncology research,” said Prof Middleton, who is leading the trial, which has received support from Portage Biotech.

Read more.

← Oxford Cancer launched at the University of Oxford
New multi-cancer early detection blood test study opens →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre